Get started
Biogen Inc.Biogen Inc.Biogen Inc.

Biogen Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsBondsETFs

BIIBCL chart


Full chart

Key facts today


Biogen (BIIB) has experienced a 7% annual sales drop over five years, with a projected 6.7% decline in the next year. The stock trades at $151.36, with a P/E ratio of 9.9.
Analyze the impactAnalyze the impact

BIIBCL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪21.12 T‬ CLP
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
10
Basic EPS (TTM)
9,800 CLP
Net income (FY)
‪1.63 T‬ CLP
Revenue (FY)
‪9.25 T‬ CLP
Shares float
‪146.34 M‬
Beta (1Y)
0.60

Employees


Employees (FY)
‪7.61 K‬
Change (1Y)
+35 +0.46%
Revenue / Employee (1Y)
‪1.22 B‬ CLP
Net income / Employee (1Y)
‪214.19 M‬ CLP

About Biogen Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher A. Viehbacher
Website
biogen.com
Headquarters
Cambridge
Founded
1978
ISIN
US09062X1037
FIGI
BBG00YFSCG08
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as BIIBCL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BIIBCL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BIIBCL highest yielding bonds


BIIB6071255
Biogen Inc. 6.45% 15-MAY-2055
Yield to maturity
5.96%
Maturity date
May 15, 2055
US9062XAD5
Biogen Inc. 5.2% 15-SEP-2045
Yield to maturity
5.85%
Maturity date
Sep 15, 2045
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
5.85%
Maturity date
Feb 15, 2051
BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050
Yield to maturity
5.83%
Maturity date
May 1, 2050
BIIB6071069
Biogen Inc. 5.75% 15-MAY-2035
Yield to maturity
5.09%
Maturity date
May 15, 2035
BIIB6071254
Biogen Inc. 5.05% 15-JAN-2031
Yield to maturity
4.44%
Maturity date
Jan 15, 2031
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030
Yield to maturity
4.38%
Maturity date
May 1, 2030
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
4.30%
Maturity date
Feb 15, 2051

See all BIIBCL bonds 

ETFs with BIIBCL exposure


VTI
Vanguard Total Stock Market ETF
Weight
0.03%
Market value
‪610.26 M‬
USD
VOO
Vanguard S&P 500 ETF
Weight
0.04%
Market value
‪484.02 M‬
USD
QQQ
Invesco QQQ Trust Series I
Weight
0.12%
Market value
‪459.10 M‬
USD
VO
Vanguard Mid-Cap ETF
Weight
0.22%
Market value
‪431.35 M‬
USD
IVV
iShares Core S&P 500 ETF
Weight
0.04%
Market value
‪270.77 M‬
USD
SPY
SPDR S&P 500 ETF Trust
Weight
0.04%
Market value
‪263.33 M‬
USD
SPY
SPDR S&P 500 ETF
Weight
0.04%
Market value
‪263.33 M‬
USD
VTV
Vanguard Value ETF
Weight
0.09%
Market value
‪172.41 M‬
USD
RSP
Invesco S&P 500 Equal Weight ETF
Weight
0.21%
Market value
‪154.06 M‬
USD
XLV
Health Care Select Sector SPDR Fund
Weight
0.42%
Market value
‪152.06 M‬
USD
IBB
iShares Biotechnology ETF
Weight
2.08%
Market value
‪130.93 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where BIIBCL is featured.

See all sparks 

Frequently Asked Questions


The current price of BIIBCL is 140,900 CLP — it hasn't changed in the past 24 hours. Watch Biogen Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BCS exchange Biogen Inc. stocks are traded under the ticker BIIBCL.
BIIBCL stock has risen by 14.09% compared to the previous week, the month change is a 14.09% rise, over the last year Biogen Inc. has showed a −17.84% decrease.
We've gathered analysts' opinions on Biogen Inc. future price: according to them, BIIBCL price has a max estimate of 250,723.24 CLP and a min estimate of 113,789.78 CLP. Watch BIIBCL chart and read a more detailed Biogen Inc. stock forecast: see what analysts think of Biogen Inc. and suggest that you do with its stocks.
BIIBCL reached its all-time high on Jun 11, 2021 with the price of 298,250 CLP, and its all-time low was 116,160 CLP and was reached on May 5, 2025. View more price dynamics on BIIBCL chart.
See other stocks reaching their highest and lowest prices.
BIIBCL stock is 1.49% volatile and has beta coefficient of 0.60. Track Biogen Inc. stock price on the chart and check out the list of the most volatile stocks — is Biogen Inc. there?
Today Biogen Inc. has the market capitalization of ‪21.12 T‬, it has increased by 9.97% over the last week.
Yes, you can track Biogen Inc. financials in yearly and quarterly reports right on TradingView.
Biogen Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
BIIBCL earnings for the last quarter are ‪5.12 K‬ CLP per share, whereas the estimation was ‪3.65 K‬ CLP resulting in a 40.31% surprise. The estimated earnings for the next quarter are ‪3.72 K‬ CLP per share. See more details about Biogen Inc. earnings.
Biogen Inc. revenue for the last quarter amounts to ‪2.47 T‬ CLP, despite the estimated figure of ‪2.18 T‬ CLP. In the next quarter, revenue is expected to reach ‪2.26 T‬ CLP.
BIIBCL net income for the last quarter is ‪593.83 B‬ CLP, while the quarter before that showed ‪229.27 B‬ CLP of net income which accounts for 159.01% change. Track more Biogen Inc. financial stats to get the full picture.
No, BIIBCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 10, 2025, the company has ‪7.61 K‬ employees. See our rating of the largest employees — is Biogen Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Biogen Inc. EBITDA is ‪2.90 T‬ CLP, and current EBITDA margin is 30.19%. See more stats in Biogen Inc. financial statements.
Like other stocks, BIIBCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biogen Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Biogen Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Biogen Inc. stock shows the sell signal. See more of Biogen Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.